A pharmaceutical composition, comprising: a compound of formula (1) in polymorphic crystalline Form A: ##STR00001## together with a pharmaceutically acceptable carrier or excipient, wherein the compound of formula (1) is present in polymorphic Form A (see, e.g., FIG. 6) substantially free of other polymorphic forms.

 
Web www.patentalert.com

< Methods and compositions for inducing tumor-specific cytotoxicity

< Compositions employing a novel human kinase

> Polypeptides and polynucleotides homologous to thymosin, ephrin a receptors, and fibromodulin

> Substituted arylketones

~ 00271